[Comparative study of relative biovailability of several spironolactone formulations in a steady-state test (author's transl)]. / Vergleichende Untersuchung der relativen Bioverfügbarkeit mehrerer Spironolacton-Zubereitungen im Steady-state-Versuch.
Arzneimittelforschung
; 29(9): 1428-32, 1979.
Article
in De
| MEDLINE
| ID: mdl-583254
By the US Food and Drug Administration spironolactone is regarded as a drug with problems related to bioavailability. A steady-state study was performed comparing the 50- and 100-mg formulations of two manufacturers with each other. Applying a fluorimetric method to both canrenone and canrenoate--the major biologically active metabolites of spironolactone--the two brands were compared in 11 volunteers for the 50 mg, and in 10 volunteers for the 100 mg dosage form.
Search on Google
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Spironolactone
Limits:
Adult
/
Female
/
Humans
/
Male
Language:
De
Journal:
Arzneimittelforschung
Year:
1979
Document type:
Article
Country of publication:
Alemania